Hoth Therapeutics shares are trading higher after the company announced HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis killed cancer cells in both gastrointestinal stromal tumors and acute myeloid leukemina.
Benzinga Newsdesk - Sep 13, 2023, 8:28AM